What is William Blair’s Forecast for ADPT FY2024 Earnings?

Adaptive Biotechnologies Co. (NASDAQ:ADPT) – William Blair increased their FY2024 earnings estimates for shares of Adaptive Biotechnologies in a research report issued on Thursday, November 14th. William Blair analyst A. Brackmann now expects that the company will earn ($1.09) per share for the year, up from their prior forecast of ($1.17). The consensus estimate for Adaptive Biotechnologies’ current full-year earnings is ($1.10) per share. William Blair also issued estimates for Adaptive Biotechnologies’ Q4 2024 earnings at ($0.23) EPS, Q1 2025 earnings at ($0.27) EPS, Q2 2025 earnings at ($0.24) EPS, Q3 2025 earnings at ($0.22) EPS, Q4 2025 earnings at ($0.20) EPS and FY2025 earnings at ($0.94) EPS.

Several other research analysts have also issued reports on ADPT. JPMorgan Chase & Co. raised their price target on shares of Adaptive Biotechnologies from $5.00 to $6.00 and gave the stock an “overweight” rating in a report on Friday, August 2nd. BTIG Research upped their price objective on Adaptive Biotechnologies from $7.00 to $8.00 and gave the company a “buy” rating in a research note on Wednesday, October 2nd. Finally, Piper Sandler raised their target price on Adaptive Biotechnologies from $6.00 to $7.00 and gave the stock an “overweight” rating in a research report on Monday, November 11th.

Adaptive Biotechnologies Stock Down 9.0 %

Shares of ADPT stock opened at $5.08 on Monday. The stock’s fifty day simple moving average is $4.95 and its 200 day simple moving average is $4.26. The firm has a market capitalization of $749.71 million, a P/E ratio of -3.79 and a beta of 1.45. Adaptive Biotechnologies has a twelve month low of $2.28 and a twelve month high of $6.70.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. BNP Paribas Financial Markets lifted its holdings in shares of Adaptive Biotechnologies by 48.8% during the 1st quarter. BNP Paribas Financial Markets now owns 63,141 shares of the company’s stock worth $203,000 after acquiring an additional 20,710 shares during the last quarter. Vanguard Group Inc. raised its position in Adaptive Biotechnologies by 0.8% during the 1st quarter. Vanguard Group Inc. now owns 12,869,818 shares of the company’s stock valued at $41,312,000 after purchasing an additional 102,134 shares during the last quarter. Acadian Asset Management LLC purchased a new stake in Adaptive Biotechnologies in the 1st quarter worth approximately $519,000. Tidal Investments LLC bought a new stake in shares of Adaptive Biotechnologies in the 1st quarter worth approximately $120,000. Finally, SG Americas Securities LLC bought a new position in shares of Adaptive Biotechnologies during the second quarter valued at approximately $78,000. Hedge funds and other institutional investors own 99.17% of the company’s stock.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.